DeCure for Intellectual disability and myopathy syndrome
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for intellectual disability and myopathy syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIntellectual disability and myopathy syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for intellectual disability and myopathy syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Endemic cretinism, caused by iodine deficiency, remains a major preventable cause of intellectual and physical disability in isolated communities in Third World countries. The condition has both myxedematous and neurological types. No drug treatment for the intellectual disability itself is described in that 1987 article.
A 2025 case report describes a 15-year-old boy with intellectual disability who was treated with GNRH analogues for inappropriate and challenging sexual behaviour. The report states that traditional treatments often fail to treat and improve such behaviour, and that alternative treatment options need to be explored. No quantitative outcomes (e.g., reduction in behaviour frequency) are given for this single case.
A 2019 review notes that people with intellectual disability have lower intelligence and difficulty with daily living, and often have many health problems. It states that most health professionals have never learned how to treat people with intellectual disability and are not confident doing so. The review does not describe any drug treatment.
A 2022 study of mouse models of Bardet-Biedl Syndrome states that intellectual disability affects 1% of the population globally and that there are limited pharmacological interventions for ID, partly due to poor understanding and the heterogeneous nature of the condition. It also notes there are limited mouse models of ID. No drug is tested in that study.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Congenital Iodine Deficiency Disorders (Endemic Cretinism): History and Description
AbstractEndemic cretinism remains a major preventable cause of intellectual and physical disability in isolated communities in Third World countries. Although endemic goitre has been studied for centuries endemic cretinism and its relationship to iodine deficiency has only been studied in more recent times. The article traces the history of endemic cretinism and describes both the myxedematous and neurological types. Etiology, pathogenesis and developmental sequelae of the condition are discussed and the physical and psychological characteristics are delineated.
Psychopharmacology Bulletin · 2025 · 2 citations · open access
Case Report: A Case of Intellectual Disability with Inappropriate and Challenging Sexual Behavior that was Treated with GNRH Analogues
AbstractIntellectual Disability starts within the course of developmental stages and covers both intellectual and adaptive deficiencies in conceptual, social and applied fields. Individuals with intellectual disability experience many difficulties in social life due to challenging and inappropriate sexual behaviour. Suchdifficulties need to be addressed, reduced or treated. Traditional treatments often fail to treat and improve suchbehavior. Alternative treatment options need to be explored with studies conducted in this field. With this paper, we aimed to show and touch on alternative treatments for challenging and inappropriate behaviors of a 15-year old boy with intellectual disability, who was treated with GNRH analogues.
Frontiers for Young Minds · 2019 · 0 citations · open access
How Can We Provide Better Healthcare for People With An Intellectual Disability?
AbstractPeople with an intellectual disability have lower intelligence than others and find it hard to do things necessary for day-to-day living, like communicating or taking care of themselves. There are different levels of intellectual disability, from mild to severe and profound. People with an intellectual disability often have many health problems, but it is often difficult for them to get good healthcare. They find it difficult to understand the complex language that many doctors and other health professionals use. Most health professionals have never learned how to treat people with an intellectual disability and they are not confident when they treat a person with an intellectual disability. Disability services and health services should work together as a team. Better healthcare for people with an intellectual disability is important, so that fewer people die because they did not get the healthcare they needed.
Iowa Research Online (The University of Iowa) · 2022 · 0 citations · open access
Behavioral and brain phenotypes of mouse models of Bardet-Biedl Syndrome
AbstractIntellectual disability (ID) is one of the most common neurodevelopmental disorders, affecting 1% of the population globally. Clinically, ID is characterized by a deficit in intellectual functioning and adaptive functioning. There are limited pharmacological interventions for ID, partially due to a poor understanding of ID and the heterogeneous nature of ID In addition, there are limited mouse models of ID.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
